Head-to-head · Cost-Efficiency Index
Intimate Rose vs VivioMD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Intimate Rose
Cost-first shoppers who want existing Intimate Rose pelvic-health customers curious about its bolt-on GLP-1 program, not comparison shoppers.
Visit Intimate RoseVivioMD
Shoppers who want both compounded and FDA-approved GLP-1 options from one nationwide platform, and don't mind completing an intake before seeing price.
Visit VivioMDThe verdict
Intimate Rose and VivioMD tie on the Cost-Efficiency Index at 53/100, so neither wins outright on the numbers. For most shoppers we'd start with Intimate Rose (ranked #368, a hair above #369) — Cost-first shoppers who want existing Intimate Rose pelvic-health customers curious about its bolt-on GLP-1 program, not comparison shoppers. But VivioMD is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Intimate Rose.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Intimate Rose | VivioMD |
|---|---|---|
| Cost-Efficiency Index | 53/100 | 53/100 |
| Semaglutide / mo | $169/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | $2,028 | — |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #368 | #369 |
Intimate Rose
53/100Where the value is
- A real, working GLP-1 telehealth funnel exists (not a dead link or vaporware page)
- The quiz states 'No payment to get started', so shoppers can get a personalized quote before committing
- Backed by an established, non-fly-by-night e-commerce brand with an existing customer base and content library
The tradeoffs
- GLP-1 is a secondary bolt-on to a pelvic-health device business, not this company's core competency — no dedicated GLP-1 clinical infrastructure is visible on the public site
- Only one undifferentiated price point ($169/month) is published — no dose tiers, no separate semaglutide vs. tirzepatide pricing, no fee itemization
Regulatory note: the FDA issued a warning letter to Intimate Rose in September 2025. We still list and link to Intimate Rose; you should know the letter is on the public record before you decide.
VivioMD
53/100Where the value is
- Offers both compounded AND FDA-approved branded GLP-1s (Ozempic, Zepbound) -- more flexibility than compounded-only competitors
- Four named pharmacy partners disclosed by name, more transparency than most peers
- Broad state coverage -- 49 states, only Louisiana excluded
The tradeoffs
- No pricing whatsoever is published -- every price is gated behind a full intake assessment
- No medical director name disclosed anywhere on the accessible pages
Regulatory note: the FDA issued a warning letter to VivioMD Group LLC dba VivioMD in June 2026. We still list and link to VivioMD; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.